Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Feb 18:5:11-9.
doi: 10.2147/copd.s8732.

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life

Marc Miravitlles  1 , Carles Llor, Jesús Molina, Karlos Naberan, Josep M Cots, Fernando Ros; EVOCA Study Group
Collaborators, Affiliations
Multicenter Study

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life

Marc Miravitlles et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Objective: To investigate the impact of exacerbations in health-related quality of life (HRQL) of patients with COPD and to compare the effect of treatment of COPD exacerbations with moxifloxacin (400 mg/day for 5 days) and amoxicillin/clavulanate (500/125 mg 3 times a day for 10 days) on HRQL.

Methods: 229 outpatients with stable COPD (mean age 68.2 years; mean FEV(1) % predicted 49.3%) participated in a prospective, observational study of 2 years' duration. The St George's Respiratory Questionnaire (SGRQ) was completed at baseline and every 6 months thereafter.

Results: COPD exacerbations (mean 2.7 episodes/patient) occurred in 136 patients (124 patients received the study medications [amoxicillin/clavulanate 54, moxifloxacin 70]). Differences between baseline and the final visit were higher for moxifloxacin compared with amoxicillin/clavulanate for total SGRQ score (-2.60 [13.1] vs 4.21 [16.2], P = 0.05) and "Symptoms" subscale (-5.64 [16.7] vs 8.27 [21], P = 0.02). The same findings were observed in patients with two or more exacerbations.

Conclusions: In COPD outpatients, treatment of exacerbations with moxifloxacin had a more favorable long-term effect on quality of life than amoxicillin/clavulanate.

Keywords: COPD; SGRQ; amoxicillin/clavulanate; exacerbations; moxifloxacin; quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Differences in the total score of the St George’s Respiratory Questionnaire (SGRQ) according to antibiotic treatment in the whole study population, in patients with one exacerbation of COPD and in those with more than one exacerbation. Standard deviation in parentheses.
See this image and copyright information in PMC

References

    1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:188–207. - PubMed
    1. Halpin DM, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3:619–623. - PubMed
    1. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med. 1999;93:173–179. - PubMed
    1. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:928–933. - PubMed
    1. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration. 2000;67:495–501. - PubMed

Publication types

Substances